RIDDLE&CODE
21.9.2021 10:07:10 CEST | Business Wire | Press release
The consortium formed by Dyne.org , RIDDLE&CODE and InfoCert , has been selected by the European Commission as one of seven contractors to develop the next version of the European Blockchain Services Infrastructure (EBSI) .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005128/en/
The award is one more milestone in the consortium's track record of excellence with cryptography and blockchain, after Dyne.org led the flagship H2020 project DECODE , RIDDLE&CODE's blockchain solutions are deployed in banking and utility markets Europe wide and InfoCert being the largest Certification Authority at European level and eIDAS certified QTSP.
The European Commission's vision for EBSI is to leverage distributed ledger technologies to create international and intra-communautaire services for public administrations. The European Blockchain Partnership aims to scale the investment fund to a fully developed platform with up to €2 billion in funding.
The consortium led by the non-profit foundation Dyne.org is developing a multilayered network of blockchains for distributed secure execution of smart contracts, including edge-computing scenarios deployed on low-power embedded devices and chips. The blockchain-agnostic solution offers compatibility with a wide range of products to grant freedom of choice to participating member states and solution developers. Existing integrations include BigchainDB, Ethereum, Hyperledger Fabric, Hyperledger Sawtooth and Bitcoin.
Dyne.org's Zenroom is the core component of the solution. Its portable and secure smart-contract execution environment works standalone (zero dependency) even in a web browser. It can be programmed in a language similar to plain English and guarantees to be functional and portable for two decades to come. Dr. Francesca Bria , president of the Italian National Innovation Fund Cassa Depositi e Prestiti comments: "Zenroom stands for Citizen Crypto. It is a core part of the DECODE tech stack for Smart Cities and it makes it easy to understand the complexity of data transformation while being compatible with any platform, including Legacy Infrastructure. We make Crypto for Citizens and we make it Open Source. "
Each member of this consortium gathers together a mature experience developing and deploying industrial standards, as well as facilitating open source community adoption of technologies, including the presence in major blockchain standardisation initiatives such as ISO TC/307, INATBA, W3C and Sovrin.
The combination of blockchain-specific hardware solutions for critical infrastructures, developed by RIDDLE&CODE, will help turn data sources into trusted ones and lay the foundation for EBSI's automated processes and scalability. The combination of InfoCert's leadership and scale when providing services for digital trust, security and identity management complying with standards will allow Europe to adopt mature blockchain solutions to mission-critical environments.
For the initial phase of EBSI's procurement, the consortium proposes a revolutionary solution for a European Digital Product Passport . As a path to success, the consortium plans to work actively to create an open "playing field" in Europe that can easily integrate a diversity of solutions and open this promising industrial field to new players from the public and private sectors.
Quote from the consortium members:
● Andrea D'Intino (EBSI Project leader, Dyne.org): "The consortium's unique combined understanding of cryptography, blockchain and identity technologies as well as its global market positioning, give us the tools and the strength to bring EBSI to the next level. We are truly excited to embrace the policy makers, the businesses and the developers into an inclusive community, to fuel their ideas and products into the European Union's blockchain. "
● Thomas Fürstner (Founder & CTO, RIDDLE&CODE): "The blockchain landscape diversifies into layer one and layer two technologies. Layer one is used for attesting values and identities with a small transaction payload and low frequency. Layer two is used for high-volume, low-value, day-to-day transactions. Then, there is the neglected but important layer zero, where blockchain meets products and goods of the physical world. This is exactly where RIDDLE&CODE contributes to EBSI ."
● Carmine Auletta (Chief Strategy and Innovation Officer, InfoCert - Tinexta Group): "Being involved in shaping the future EU blockchain infrastructure not only makes us extremely proud, it also could have an important strategic impact on our reference market. An EU blockchain infrastructure could represent the backbone on which EU Trust will be built in the future. " He further commented: "InfoCert, as the leading Qualified Trust Service Provider in the EU, aims to further strengthen its thought leadership role in a constantly evolving market. InfoCert has an impressive track record in building innovative solutions and an ambitious R&D program focused on Digital Identity and Digital Trust. It includes the exploitation of emerging technologies, among which blockchain is one of the most promising. Our partners have tremendous technical competencies in distributed ledger technologies, while InfoCert has very distinctive expertise in building Trust Frameworks. Joining forces was natural and proved to be crucial in the success of our consortium. "
About RIDDLE&CODE
RIDDLE&CODE is Europe's leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.
More information: www.riddleandcode.com
About Dyne.org
Dyne.org is a non-profit foundation dedicated to free and open source software and community development with 20 years of expertise in developing applications used worldwide. Its motto is "we are free to share code and we code to share freedom" and other projects include independent streaming software for free speech, privacy tools for activists and GNU/Linux distributions.
More information: dyne.org
About InfoCert
InfoCert, Tinexta Group, is the largest European Certification Authority, active in over twenty countries. The company provides services in digitisation, eDelivery, Digital Signature and digital preservation of documents and is an accredited AgID digital identity operator in the area of SPID (Public System for the management of Digital Identity). The company holds a 51% stake in Camerfirma, one of the principal Spanish certification authorities and a 16.7% stake in Authada, a leading-edge German Identity Provider.
More information: infocert.digital
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005128/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom